Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Selma Ugurel

Showing results (171-180 of 265) with videos related to

Pageof 27
Sort By:
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|January 15, 2020
Predominance of Central Memory T Cells with High T-Cell Receptor Repertoire Diversity is Associated with Response to PD-1/PD-L1 Inhibition in Merkel Cell CarcinomaIvelina Spassova, Selma Ugurel, Patrick Terheyden, et al.
Nature Communications|July 19, 2023
Retraction Note: TRIB2 confers resistance to anti-cancer therapy by activating the serine/threonine protein kinase AKTRichard Hill, Patricia A Madureira, Bibiana Ferreira, et al.
Oncotarget|November 8, 2017
Evaluation of real-world treatment outcomes in patients with distant metastatic Merkel cell carcinoma following second-line chemotherapy in EuropeJürgen C Becker, Eva Lorenz, Selma Ugurel, et al.
European Journal of Cancer (Oxford, England : 1990)|March 8, 2025
pTERT mutational status is associated with survival in stage IV melanoma patients receiving first-line immune therapyPhilipp Jansen, Wolfgang Galetzka, Carl M Thielmann, et al.
Cancer Immunology, Immunotherapy : CII|May 9, 2012
Survivin-specific T-cell reactivity correlates with tumor response and patient survival: a phase-II peptide vaccination trial in metastatic melanomaJürgen C Becker, Mads H Andersen, Valeska Hofmeister-Müller, et al.
Clinical and Translational Medicine|November 2, 2022
Circulating cell-free messenger RNA enables non-invasive pan-tumour monitoring of melanoma therapy independent of the mutational genotypeLea Jessica Albrecht, Anna Höwner, Klaus Griewank, et al.
Frontiers in Oncology|August 22, 2024
Single-cell RNA and T-cell receptor sequencing unveil mycosis fungoides heterogeneity and a possible gene signatureNalini Srinivas, Lukas Peiffer, Kai Horny, et al.
Journal Der Deutschen Dermatologischen Gesellschaft = Journal of the German Society of Dermatology : JDDG|May 7, 2019
S2k guidelines for Merkel cell carcinoma (MCC, neuroendocrine carcinoma of the skin) - update 2018Jürgen C Becker, Thomas Eigentler, Bernhard Frerich, et al.
European Journal of Cancer (Oxford, England : 1990)|March 31, 2021
Leptomeningeal disease from melanoma-Poor prognosis despite new therapeutic modalitiesEleftheria Chorti, Sied Kebir, Misbah S Ahmed, et al.
Journal Der Deutschen Dermatologischen Gesellschaft = Journal of the German Society of Dermatology : JDDG|May 23, 2019
S2k-Leitlinie Merkelzellkarzinom (MZK, MCC, neuroendokrines Karzinom der Haut) - Update 2018Jürgen C Becker, Thomas Eigentler, Bernhard Frerich, et al.
Pageof 27

Showing results (171-180 of 265) with videos related to

Sort By:
Pageof 27
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|January 15, 2020
Predominance of Central Memory T Cells with High T-Cell Receptor Repertoire Diversity is Associated with Response to PD-1/PD-L1 Inhibition in Merkel Cell CarcinomaIvelina Spassova, Selma Ugurel, Patrick Terheyden, et al.
Nature Communications|July 19, 2023
Retraction Note: TRIB2 confers resistance to anti-cancer therapy by activating the serine/threonine protein kinase AKTRichard Hill, Patricia A Madureira, Bibiana Ferreira, et al.
Oncotarget|November 8, 2017
Evaluation of real-world treatment outcomes in patients with distant metastatic Merkel cell carcinoma following second-line chemotherapy in EuropeJürgen C Becker, Eva Lorenz, Selma Ugurel, et al.
European Journal of Cancer (Oxford, England : 1990)|March 8, 2025
pTERT mutational status is associated with survival in stage IV melanoma patients receiving first-line immune therapyPhilipp Jansen, Wolfgang Galetzka, Carl M Thielmann, et al.
Cancer Immunology, Immunotherapy : CII|May 9, 2012
Survivin-specific T-cell reactivity correlates with tumor response and patient survival: a phase-II peptide vaccination trial in metastatic melanomaJürgen C Becker, Mads H Andersen, Valeska Hofmeister-Müller, et al.
Clinical and Translational Medicine|November 2, 2022
Circulating cell-free messenger RNA enables non-invasive pan-tumour monitoring of melanoma therapy independent of the mutational genotypeLea Jessica Albrecht, Anna Höwner, Klaus Griewank, et al.
Frontiers in Oncology|August 22, 2024
Single-cell RNA and T-cell receptor sequencing unveil mycosis fungoides heterogeneity and a possible gene signatureNalini Srinivas, Lukas Peiffer, Kai Horny, et al.
Journal Der Deutschen Dermatologischen Gesellschaft = Journal of the German Society of Dermatology : JDDG|May 7, 2019
S2k guidelines for Merkel cell carcinoma (MCC, neuroendocrine carcinoma of the skin) - update 2018Jürgen C Becker, Thomas Eigentler, Bernhard Frerich, et al.
European Journal of Cancer (Oxford, England : 1990)|March 31, 2021
Leptomeningeal disease from melanoma-Poor prognosis despite new therapeutic modalitiesEleftheria Chorti, Sied Kebir, Misbah S Ahmed, et al.
Journal Der Deutschen Dermatologischen Gesellschaft = Journal of the German Society of Dermatology : JDDG|May 23, 2019
S2k-Leitlinie Merkelzellkarzinom (MZK, MCC, neuroendokrines Karzinom der Haut) - Update 2018Jürgen C Becker, Thomas Eigentler, Bernhard Frerich, et al.
Pageof 27